MacroGenics, Inc. (MGNX) 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025, for MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer. The company operates a commercial-scale cGMP manufacturing facility in Rockville, Maryland, and maintains a pipeline of proprietary product candidates including lorigerlimab, MGC026, and MGC028. MacroGenics also retains economic rights to three FDA-approved products (ZYNYZ, MARGENZA, and TZIELD) through strategic collaborations with Incyte, TerSera, and Sanofi, respectively.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $149.5 million | $150.0 million |
| Net Loss | $(74.6) million | $(67.0) million |
| Operating Cash Flow | $(81.0) million | $(68.4) million |
| Cash and Marketable Securities (Dec 31) | $189.9 million | $201.7 million |
| Accumulated Deficit | $(1.24) billion | $(1.17) billion |
| Research & Development Expense | $147.2 million | $177.2 million |
Note: The filing text does not provide a specific gross margin percentage for the aggregate business, though cost of manufacturing services was $36.0 million against $52.6 million in contract manufacturing revenue.
Material Changes vs. Prior Period
- Revenue Composition: Total revenue remained flat year-over-year. However, the mix shifted significantly. Contract manufacturing revenue surged 302% to $52.6 million due to increased external client production. Conversely, revenue from collaborative agreements dropped 27% to $87.2 million, primarily because 2024 included a $100 million milestone from Incyte that was not repeated in 2025. Product sales from MARGENZA dropped to zero following the sale of global rights to TerSera in late 2024.
- Expense Reduction: R&D expenses decreased 17% to $147.2 million, driven by the discontinuation of the vobra duo program and the wind-down of MARGENZA activities. SG&A expenses fell 45% to $39.2 million, largely due to reduced stock-based compensation and professional fees.
- Asset Monetization: In June 2025, the company sold a capped royalty interest in ZYNYZ to Sagard Healthcare Partners for $70.0 million. This was recorded as a financing liability, resulting in $8.3 million of non-cash interest expense in 2025.
Guidance, Outlook, and Risks
Liquidity and Runway: Management anticipates that current cash, cash equivalents, marketable securities, and anticipated partner payments will fund operations into late 2027. The company is executing cost-reduction initiatives to extend this runway.
Clinical Developments and Risks:
- Lorigerlimab (LINNET Study): In February 2026, the FDA initiated a partial clinical hold on the LINNET study due to safety events (Grade 4 thrombocytopenia, myocarditis, and neutropenia/septic shock) in four patients. No new patients will be enrolled until the hold is lifted.
- Lorigerlimab (LORIKEET Trial): In November 2025, the company discontinued development of lorigerlimab in second-line metastatic castration-resistant prostate cancer (mCRPC) after interim data failed to meet the primary endpoint for progression-free survival.
- Partnerships: Gilead exercised an option in November 2025 to license a second preclinical research program, triggering a $25 million payment. Sanofi triggered $50 million in milestone payments for TZIELD approvals in the UK and China.
- Regulatory Risks: The company faces significant uncertainty regarding the FDA clinical hold on lorigerlimab and the potential impact of new healthcare legislation (e.g., the "One Big Beautiful Bill Act") on reimbursement and pricing.
Investor Verification Checklist
- Clinical Hold Status: Verify the timeline and resolution path for the FDA partial clinical hold on the lorigerlimab LINNET study.
- Cash Runway: Confirm the sufficiency of the $189.9 million cash position against the projected burn rate, considering the potential need for additional capital if clinical trials are delayed.
- Royalty Monetization Liability: Review the assumptions used to calculate the effective interest rate (approx. 24.3%) for the $70 million Sagard royalty sale liability.
- Manufacturing Utilization: Assess the sustainability of the 302% increase in contract manufacturing revenue and the associated cost structure.
- Partnership Milestones: Monitor upcoming regulatory decisions for TZIELD (Stage 3 T1D) and ZYNYZ (SCAC) that could trigger significant milestone payments.